Pushkal P. Garg's most recent trade in Alnylam Pharmaceuticals Inc was a trade of 767 Common Stock done at an average price of $323.8 . Disclosure was reported to the exchange on March 4, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 323.84 per share. | 04 Mar 2026 | 767 | 21,577 (0%) | 0% | 323.8 | 248,385 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 323.55 per share. | 04 Mar 2026 | 740 | 19,703 (0%) | 0% | 323.6 | 239,427 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 322.33 per share. | 04 Mar 2026 | 654 | 20,443 (0%) | 0% | 322.3 | 210,804 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 324.59 per share. | 04 Mar 2026 | 510 | 19,193 (0%) | 0% | 324.6 | 165,541 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 326.08 per share. | 04 Mar 2026 | 500 | 18,693 (0%) | 0% | 326.1 | 163,040 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 323.01 per share. | 04 Mar 2026 | 350 | 22,344 (0%) | 0% | 323.0 | 113,054 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 321.82 per share. | 04 Mar 2026 | 289 | 22,694 (0%) | 0% | 321.8 | 93,006 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 324.88 per share. | 04 Mar 2026 | 272 | 21,305 (0%) | 0% | 324.9 | 88,367 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 320.81 per share. | 04 Mar 2026 | 215 | 22,983 (0%) | 0% | 320.8 | 68,974 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 325.67 per share. | 04 Mar 2026 | 208 | 21,097 (0%) | 0% | 325.7 | 67,739 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 319.03 per share. | 04 Mar 2026 | 106 | 23,300 (0%) | 0% | 319.0 | 33,817 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 320.01 per share. | 04 Mar 2026 | 102 | 23,198 (0%) | 0% | 320.0 | 32,641 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jan 2026 | 3,800 | 24,021 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 365.56 per share. | 11 Jan 2026 | 220 | 22,803 (0%) | 0% | 365.6 | 80,423 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 364.83 per share. | 11 Jan 2026 | 199 | 23,023 (0%) | 0% | 364.8 | 72,601 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 360.22 per share. | 11 Jan 2026 | 155 | 23,440 (0%) | 0% | 360.2 | 55,834 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 358.18 per share. | 11 Jan 2026 | 123 | 23,680 (0%) | 0% | 358.2 | 44,056 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 361.45 per share. | 11 Jan 2026 | 98 | 23,342 (0%) | 0% | 361.4 | 35,422 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 357.17 per share. | 11 Jan 2026 | 96 | 23,803 (0%) | 0% | 357.2 | 34,288 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 368.62 per share. | 11 Jan 2026 | 92 | 22,620 (0%) | 0% | 368.6 | 33,913 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 359.14 per share. | 11 Jan 2026 | 85 | 23,595 (0%) | 0% | 359.1 | 30,527 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 362.38 per share. | 11 Jan 2026 | 73 | 23,269 (0%) | 0% | 362.4 | 26,454 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 366.42 per share. | 11 Jan 2026 | 50 | 22,753 (0%) | 0% | 366.4 | 18,321 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 363.55 per share. | 11 Jan 2026 | 47 | 23,222 (0%) | 0% | 363.6 | 17,087 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 355.17 per share. | 11 Jan 2026 | 42 | 23,940 (0%) | 0% | 355.2 | 14,917 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 356.10 per share. | 11 Jan 2026 | 41 | 23,899 (0%) | 0% | 356.1 | 14,600 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 367.39 per share. | 11 Jan 2026 | 41 | 22,712 (0%) | 0% | 367.4 | 15,063 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 369.48 per share. | 11 Jan 2026 | 40 | 22,580 (0%) | 0% | 369.5 | 14,779 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 353.95 per share. | 11 Jan 2026 | 39 | 23,982 (0%) | 0% | 353.9 | 13,804 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 375.63 per share. | 11 Jan 2026 | 19 | 22,526 (0%) | 0% | 375.6 | 7,137 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 370.89 per share. | 11 Jan 2026 | 18 | 22,562 (0%) | 0% | 370.9 | 6,676 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 377.80 per share. | 11 Jan 2026 | 15 | 22,511 (0%) | 0% | 377.8 | 5,667 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 374.43 per share. | 11 Jan 2026 | 14 | 22,545 (0%) | 0% | 374.4 | 5,242 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 372.33 per share. | 11 Jan 2026 | 3 | 22,559 (0%) | 0% | 372.3 | 1,117 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 3,108 | 23,329 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Oct 2025 | 2,851 | 26,180 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 451.76 per share. | 01 Oct 2025 | 898 | 20,853 (0%) | 0% | 451.8 | 405,680 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 450.63 per share. | 01 Oct 2025 | 810 | 21,751 (0%) | 0% | 450.6 | 365,010 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 449.99 per share. | 01 Oct 2025 | 682 | 22,561 (0%) | 0% | 450.0 | 306,893 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 452.69 per share. | 01 Oct 2025 | 668 | 24,039 (0%) | 0% | 452.7 | 302,397 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 450.81 per share. | 01 Oct 2025 | 541 | 25,039 (0%) | 0% | 450.8 | 243,888 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 453.51 per share. | 01 Oct 2025 | 417 | 20,436 (0%) | 0% | 453.5 | 189,114 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 451.86 per share. | 01 Oct 2025 | 332 | 24,707 (0%) | 0% | 451.9 | 150,018 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 453.77 per share. | 01 Oct 2025 | 329 | 23,710 (0%) | 0% | 453.8 | 149,290 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 449.79 per share. | 01 Oct 2025 | 249 | 25,580 (0%) | 0% | 449.8 | 111,998 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 454.84 per share. | 01 Oct 2025 | 244 | 23,466 (0%) | 0% | 454.8 | 110,981 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 454.37 per share. | 01 Oct 2025 | 215 | 20,221 (0%) | 0% | 454.4 | 97,690 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 448.77 per share. | 01 Oct 2025 | 180 | 25,829 (0%) | 0% | 448.8 | 80,779 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 457.43 per share. | 01 Oct 2025 | 147 | 23,246 (0%) | 0% | 457.4 | 67,242 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 446.53 per share. | 01 Oct 2025 | 115 | 26,065 (0%) | 0% | 446.5 | 51,351 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 455.82 per share. | 01 Oct 2025 | 73 | 23,393 (0%) | 0% | 455.8 | 33,275 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 447.93 per share. | 01 Oct 2025 | 56 | 26,009 (0%) | 0% | 447.9 | 25,084 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 457.67 per share. | 01 Oct 2025 | 3 | 23,243 (0%) | 0% | 457.7 | 1,373 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Aug 2025 | 2,851 | 23,072 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 454.04 per share. | 15 Aug 2025 | 543 | 21,929 (0%) | 0% | 454.0 | 246,544 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 457.26 per share. | 15 Aug 2025 | 338 | 21,062 (0%) | 0% | 457.3 | 154,554 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 452.96 per share. | 15 Aug 2025 | 329 | 22,472 (0%) | 0% | 453.0 | 149,024 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 461.01 per share. | 15 Aug 2025 | 305 | 20,266 (0%) | 0% | 461.0 | 140,608 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 455.41 per share. | 15 Aug 2025 | 276 | 21,400 (0%) | 0% | 455.4 | 125,693 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 459.59 per share. | 15 Aug 2025 | 260 | 20,571 (0%) | 0% | 459.6 | 119,493 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 454.84 per share. | 15 Aug 2025 | 241 | 21,688 (0%) | 0% | 454.8 | 109,616 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 458.27 per share. | 15 Aug 2025 | 231 | 20,831 (0%) | 0% | 458.3 | 105,860 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 451.99 per share. | 15 Aug 2025 | 103 | 22,801 (0%) | 0% | 452.0 | 46,555 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 449.92 per share. | 15 Aug 2025 | 90 | 22,943 (0%) | 0% | 449.9 | 40,493 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 461.73 per share. | 15 Aug 2025 | 45 | 20,221 (0%) | 0% | 461.7 | 20,778 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 450.92 per share. | 15 Aug 2025 | 39 | 22,904 (0%) | 0% | 450.9 | 17,586 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 447.97 per share. | 15 Aug 2025 | 39 | 23,033 (0%) | 0% | 448.0 | 17,471 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | EVP Chief R&D | Sale of securities on an exchange or to another person at price $ 455.83 per share. | 15 Aug 2025 | 12 | 21,676 (0%) | 0% | 455.8 | 5,470 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 300.00 per share. | 21 Mar 2025 | 5,445 | 20,221 (0%) | 0% | 300 | 1,633,500 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 42.22 per share. | 21 Mar 2025 | 5,445 | 25,666 (0%) | 0% | 42.2 | 229,888 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Mar 2025 | 5,445 | 0 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 285.00 per share. | 21 Mar 2025 | 4,321 | 20,221 (0%) | 0% | 285 | 1,231,485 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 14,137 | 27,099 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 7,819 | 7,819 | - | - | Stock Option (right to buy) | |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 243.13 per share. | 03 Mar 2025 | 583 | 25,740 (0%) | 0% | 243.1 | 141,745 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 240.92 per share. | 03 Mar 2025 | 343 | 24,860 (0%) | 0% | 240.9 | 82,636 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 244.43 per share. | 03 Mar 2025 | 273 | 25,467 (0%) | 0% | 244.4 | 66,729 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 243.36 per share. | 03 Mar 2025 | 235 | 26,651 (0%) | 0% | 243.4 | 57,190 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 242.37 per share. | 03 Mar 2025 | 213 | 26,886 (0%) | 0% | 242.4 | 51,625 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 241.60 per share. | 03 Mar 2025 | 198 | 24,662 (0%) | 0% | 241.6 | 47,837 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 244.41 per share. | 03 Mar 2025 | 158 | 26,493 (0%) | 0% | 244.4 | 38,617 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 239.25 per share. | 03 Mar 2025 | 147 | 25,203 (0%) | 0% | 239.3 | 35,170 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 242.70 per share. | 03 Mar 2025 | 120 | 24,542 (0%) | 0% | 242.7 | 29,124 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 245.53 per share. | 03 Mar 2025 | 117 | 25,350 (0%) | 0% | 245.5 | 28,727 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 245.26 per share. | 03 Mar 2025 | 116 | 26,377 (0%) | 0% | 245.3 | 28,450 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 246.19 per share. | 03 Mar 2025 | 48 | 26,329 (0%) | 0% | 246.2 | 11,817 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 247.40 per share. | 03 Mar 2025 | 5 | 26,324 (0%) | 0% | 247.4 | 1,237 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 248.00 per share. | 03 Mar 2025 | 1 | 26,323 (0%) | 0% | 248 | 248 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 1,908 | 1,908 | - | - | Restricted Stock Units | |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Feb 2025 | 1,908 | 13,897 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 242.44 per share. | 27 Feb 2025 | 352 | 13,173 (0%) | 0% | 242.4 | 85,339 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 241.51 per share. | 27 Feb 2025 | 149 | 13,525 (0%) | 0% | 241.5 | 35,985 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 243.23 per share. | 27 Feb 2025 | 142 | 13,031 (0%) | 0% | 243.2 | 34,539 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 240.32 per share. | 27 Feb 2025 | 91 | 13,674 (0%) | 0% | 240.3 | 21,869 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 244.12 per share. | 27 Feb 2025 | 69 | 12,962 (0%) | 0% | 244.1 | 16,844 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 236.51 per share. | 27 Feb 2025 | 51 | 13,846 (0%) | 0% | 236.5 | 12,062 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 239.17 per share. | 27 Feb 2025 | 41 | 13,765 (0%) | 0% | 239.2 | 9,806 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 238.32 per share. | 27 Feb 2025 | 40 | 13,806 (0%) | 0% | 238.3 | 9,533 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 3,109 | 15,098 (0%) | 0% | 0 | Common Stock | |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 250.11 per share. | 13 Feb 2025 | 862 | 12,675 (0%) | 0% | 250.1 | 215,595 | Common Stock |
| Alnylam Pharma Inc | Pushkal P. Garg | CMO & EVP Dev & Med Affairs | Sale of securities on an exchange or to another person at price $ 253.37 per share. | 13 Feb 2025 | 386 | 14,363 (0%) | 0% | 253.4 | 97,801 | Common Stock |